Search

everythinglearnresearchcommunity

for

Search:↓

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The user is experiencing significant hair shedding after starting RU58841, despite using dutasteride and oral minoxidil for over a year without stabilization. Others suggest continuing the treatment as shedding can be a normal phase, but caution that RU58841 is unpredictable.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

Scientists found hidden stem cells that might reactivate hair growth. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

The conversation is about a user's progress in treating diffuse hair thinning using a topical regimen including finasteride, minoxidil, ketoconazole, microneedling, saw palmetto, collagen, and vitamins, along with lifestyle changes. The user plans to switch from topical to oral finasteride for potentially better results.

A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.

A 42-year-old had 2,100 grafts transplanted to the frontal third of the scalp, using treatments like Dutasteride, oral Minoxidil, ketoconazole shampoo, dermarolling, and PRP. They plan to add RU58841 and have scheduled SMP to improve cosmetic results.

PP405 shows promise for hair growth but may need continuous use like Minoxidil. Current treatments include Minoxidil, finasteride, and dutasteride, with skepticism about a true cure due to financial interests.

Stemson raised $15M for hair cloning, with hopes it becomes a reality in 10-20 years. Users are hopeful and discuss using Minoxidil and finasteride in the meantime.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

Hair loss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.

The user is treating hair loss with topical Minoxidil, Finasteride, RU58841, microneedling, and Ketoconazole. For grey hair, they use L-Cysteine, L-Methionine, and PABA, and have noticed some re-pigmentation.

The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.

A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

The conversation is about people with advanced hair loss (Norwood 6 or 7) who have seen significant hair regrowth using treatments like finasteride, minoxidil, microneedling, and RU58841. Nine cases were collected to motivate others to try these treatments despite advanced hair loss.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

A user shared progress pictures showing improved hair fullness after 75 days using 2.5mg oral minoxidil daily, 1mg oral finasteride every other day, a 1.5mm dermastamp weekly, and daily scalp massages. They report seeing early positive results.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

A 27-year-old user shared their 7-week progress using topical finasteride 0.3% and minoxidil 6% daily, along with keto 2% shampoo twice a week and derma needling every 2-3 weeks. They reported no side effects.

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

Topical Minoxidil and RU58841 can make hair look brittle and thin, possibly due to the propylene glycol in their solutions. Some users experience side effects like heart palpitations with RU58841, while others have no issues.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.